J Cosmet Dermatol. 2026 Feb;25(2):e70656. doi: 10.1111/jocd.70656.
ABSTRACT
BACKGROUND: Intradermal botulinum toxin injections have been shown to reduce sebaceous gland activity and improve skin texture in patients with oily and acne-prone skin. However, needle-based application is associated with discomfort and potential side effects.
OBJECTIVE: To evaluate the clinical efficacy and safety of transdermal delivery of botulinum toxin (150 kDa) using Transdermal Application (TDA) technology for the treatment of oily and acne-prone skin.
METHODS: In this single-center observational study, 19 participants (aged 20-50) underwent treatment with the DERMADROP MED TDA device according to the BIOBOTOX protocol. Objective assessments included Sebumeter measurements and 2D/3D skin imaging. Subjective evaluation was conducted using validated patient-reported outcome measures (OSIS, OSSAS) at baseline, 2 weeks, and 4 weeks posttreatment.
RESULTS: A statistically significant reduction in sebum levels was observed, accompanied by notable improvements in self-reported skin clarity and satisfaction. No adverse events were reported.
CONCLUSION: Transdermal application of botulinum toxin using TDA-based DERMADROP MED technology is a safe, well-tolerated, and effective noninvasive treatment modality for reducing sebaceous activity and improving the appearance of oily and acne-prone skin.
PMID:41652824 | DOI:10.1111/jocd.70656
